Cytokine-Mediated
Human Beta Cell Inflammation Assay
REVEALING YOUR DRUG POTENTIAL USING A HUMAN PATHOLOGICALLY RELEVANT TYPE 1 AND TYPE 2 DIABETES-MEDIATED INFLAMMATION ASSAY
Evaluate the anti-inflammatory and beta cell protection potential of your drug compounds
Inflammation is a major and complex component of pathogenic processes in type 1 and type 2 diabetes mellitus. In type 1 diabetes, inflammation is a primary event that persists and intensifies as the disease progresses, whereas in type 2 diabetes, inflammation is a chronic feature. In both types of diabetes, the phenomenon involves inflammatory cytokines and is responsible for impaired insulin secretion and the destruction of pancreatic beta cells, making it a central strategy for drug discovery activities targeting Diabetes. Using Endoc-βH5® cells, this assay reproduces the clinically observed response of human pancreatic beta cells to cytokine-induced inflammation. It enables you to assess the pharmacological efficacy of your drug discovery strategies aiming to modulate inflammatory response and protect beta cells from inflammation.
FEATURES & BENEFITS
A unique humanized and pharmacologically validated assay
Recapitulates in vitro the cytokine-mediated inflammation process of type 2 and type 1 diabetes
ASSAY CONCEPT
APPLICATIONS
READOUTS
HAVE A PROJECT IN MIND?
Human Cell Design team of experts can offer you tailored assays and EndoC-βH5® derived cell models.